LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akcijų sąrašas・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

23.35 0.73

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.96

Max

23.52

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-56M -185M
Pardavimai	-71M 136M
Pelnas, tenkantis vienai akcijai	-1.54
Pelno marža	-136.029
Darbuotojai	1,371
EBITDA	-56M -161M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+124.16% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-136M 2.3B
Ankstesnė atidarymo kaina	22.62
Ankstesnė uždarymo kaina	23.35

Naujienos nuotaikos

By Acuity

61%

39%

278 / 344 reitingas Healthcare

Ultragenyx Pharmaceutical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-27 21:33; UTC

Uždarbis

Correction to Salesforce 1Q Sales, Profit Rise Article

2026-05-27 21:00; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026-05-27 20:18; UTC

Uždarbis

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026-05-27 23:49; UTC

Rinkos pokalbiai

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026-05-27 23:39; UTC

Rinkos pokalbiai

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-27 23:08; UTC

Rinkos pokalbiai

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026-05-27 22:21; UTC

Rinkos pokalbiai

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026-05-27 21:29; UTC

Karštos akcijos

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026-05-27 21:08; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026-05-27 21:02; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026-05-27 20:59; UTC

Įsigijimai, susijungimai, perėmimai

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026-05-27 20:55; UTC

Uždarbis

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026-05-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-27 20:48; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026-05-27 20:45; UTC

Uždarbis

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026-05-27 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Webster Financial Stockholders Approve Sale to Banco Santander

2026-05-27 20:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026-05-27 20:30; UTC

Uždarbis

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026-05-27 20:30; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026-05-27 20:22; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:16; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026-05-27 20:13; UTC

Uždarbis

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Akcijų palyginimas

Kainos pokytis

Ultragenyx Pharmaceutical Inc Prognozė

Kainos tikslas

By TipRanks

124.16% į viršų

12 mėnesių prognozė

Vidutinis 51.87 USD 124.16%

Aukščiausias 96 USD

Žemiausias 25 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ultragenyx Pharmaceutical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

Pirkti

Laikyti

Parduoti

Remiantis 16 analitikų, pateikusių Ultragenyx Pharmaceutical Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

278 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.